Autoimmune disorder therapeutic - Vibrant Therapeutics
Latest Information Update: 27 Apr 2026
At a glance
- Originator Vibrant Therapeutics
- Class Antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 02 Mar 2026 Autoimmune disorder therapeutic - Vibrant Therapeutics is available for licensing as of 02 Mar 2026. https://www.vibrantx.com/
- 02 Mar 2026 Preclinical trials in Autoimmune disorders in China (Parenteral) prior to March 2026 (Vibrant Therapeutics pipeline, March 2026)